Cargando…
NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells
Strong experimental evidence in animal and cellular models supports a pivotal role of sphingosine kinase‐1 (SK1) in oncogenesis. In many human cancers, SK1 levels are upregulated and these increases are linked to poor prognosis in patients. Here, by employing untargeted NMR‐based metabolomic profili...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527469/ https://www.ncbi.nlm.nih.gov/pubmed/28258651 http://dx.doi.org/10.1002/1878-0261.12048 |
_version_ | 1783252967775797248 |
---|---|
author | Bernacchioni, Caterina Ghini, Veronica Cencetti, Francesca Japtok, Lukasz Donati, Chiara Bruni, Paola Turano, Paola |
author_facet | Bernacchioni, Caterina Ghini, Veronica Cencetti, Francesca Japtok, Lukasz Donati, Chiara Bruni, Paola Turano, Paola |
author_sort | Bernacchioni, Caterina |
collection | PubMed |
description | Strong experimental evidence in animal and cellular models supports a pivotal role of sphingosine kinase‐1 (SK1) in oncogenesis. In many human cancers, SK1 levels are upregulated and these increases are linked to poor prognosis in patients. Here, by employing untargeted NMR‐based metabolomic profiling combined with functional validations, we report the crucial role of SK1 in the metabolic shift known as the Warburg effect in A2780 ovarian cancer cells. Indeed, expression of SK1 induced a high glycolytic rate, characterized by increased levels of lactate along with increased expression of the proton/monocarboxylate symporter MCT1, and decreased oxidative metabolism, associated with the accumulation of intermediates of the tricarboxylic acid cycle and reduction in CO(2) production. Additionally, SK1‐expressing cells displayed a significant increase in glucose uptake paralleled by GLUT3 transporter upregulation. The role of SK1 is not limited to the induction of aerobic glycolysis, affecting metabolic pathways that appear to support the biosynthesis of macromolecules. These findings highlight the role of SK1 signaling axis in cancer metabolic reprogramming, pointing out innovative strategies for cancer therapies. |
format | Online Article Text |
id | pubmed-5527469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55274692017-08-15 NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells Bernacchioni, Caterina Ghini, Veronica Cencetti, Francesca Japtok, Lukasz Donati, Chiara Bruni, Paola Turano, Paola Mol Oncol Research Articles Strong experimental evidence in animal and cellular models supports a pivotal role of sphingosine kinase‐1 (SK1) in oncogenesis. In many human cancers, SK1 levels are upregulated and these increases are linked to poor prognosis in patients. Here, by employing untargeted NMR‐based metabolomic profiling combined with functional validations, we report the crucial role of SK1 in the metabolic shift known as the Warburg effect in A2780 ovarian cancer cells. Indeed, expression of SK1 induced a high glycolytic rate, characterized by increased levels of lactate along with increased expression of the proton/monocarboxylate symporter MCT1, and decreased oxidative metabolism, associated with the accumulation of intermediates of the tricarboxylic acid cycle and reduction in CO(2) production. Additionally, SK1‐expressing cells displayed a significant increase in glucose uptake paralleled by GLUT3 transporter upregulation. The role of SK1 is not limited to the induction of aerobic glycolysis, affecting metabolic pathways that appear to support the biosynthesis of macromolecules. These findings highlight the role of SK1 signaling axis in cancer metabolic reprogramming, pointing out innovative strategies for cancer therapies. John Wiley and Sons Inc. 2017-03-30 2017-05 /pmc/articles/PMC5527469/ /pubmed/28258651 http://dx.doi.org/10.1002/1878-0261.12048 Text en © 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Bernacchioni, Caterina Ghini, Veronica Cencetti, Francesca Japtok, Lukasz Donati, Chiara Bruni, Paola Turano, Paola NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title | NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title_full | NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title_fullStr | NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title_full_unstemmed | NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title_short | NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
title_sort | nmr metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527469/ https://www.ncbi.nlm.nih.gov/pubmed/28258651 http://dx.doi.org/10.1002/1878-0261.12048 |
work_keys_str_mv | AT bernacchionicaterina nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT ghiniveronica nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT cencettifrancesca nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT japtoklukasz nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT donatichiara nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT brunipaola nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells AT turanopaola nmrmetabolomicshighlightssphingosinekinase1asanewmolecularswitchintheorchestrationofaberrantmetabolicphenotypeincancercells |